Steroids and immunosuppressant drugs in myasthenia gravis
- 20 May 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Neurology
- Vol. 4 (6), 317-327
- https://doi.org/10.1038/ncpneuro0810
Abstract
In chronic autoimmune conditions such as myasthenia gravis (MG), immunosuppression--usually long-term--is often necessary. The mechanisms of action of immunosuppressant drugs in MG fall into three main categories: inhibition of the cell cycle (azathioprine, cyclophosphamide, methotrexate and mycophenolate mofetil), immunosuppression of T cells (steroids, ciclosporin and tacrolimus), and B-cell depletion (rituximab). Data on immunosuppressant drugs in MG derive mainly from clinical experience, observational studies and expert opinion. The main drawbacks of the randomized evidence are the small size of most drug trials, variations in study design, and a lack of head-to-head studies. It is therefore difficult to determine the relative efficacy of each immunosuppressant. Oral prednisolone, usually started at a low dose on an alternate-day regimen, and gradually increased, is the recommended first-choice short-term immunosuppressant. Long-term immunosuppression regimens vary between different countries and physicians. Azathioprine is often the first-choice drug for long-term immunosuppression, and it is usually started together with steroids to allow tapering of steroids to the lowest dose possible. Methotrexate, mycophenolate mofetil or tacrolimus should be considered in patients who are intolerant of or unresponsive to azathioprine. Ciclosporin and cyclophosphamide should only be considered as a last resort, as these drugs can cause serious adverse events. Data on rituximab use in MG are sparse, but the initial results are promising.Keywords
This publication has 49 references indexed in Scilit:
- Frequency of seronegativity in adult‐acquired generalized myasthenia gravisMuscle & Nerve, 2007
- Myasthenia gravis: past, present, and futureJCI Insight, 2006
- B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic targetPharmacology & Therapeutics, 2006
- Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacyCritical Reviews in Oncology/Hematology, 2005
- Myasthenia gravisThe Lancet, 2001
- Immunosuppressive drugs: the first 50 years and a glance forwardImmunopharmacology, 2000
- Myasthenia GravisNew England Journal of Medicine, 1994
- Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.Journal of Neurology, Neurosurgery & Psychiatry, 1985
- OBSERVATIONS OF THE NATURAL HISTORY OF MYASTHENIA GRAVIS AND THE EFFECT OF THYMECTOMYAnnals of the New York Academy of Sciences, 1981
- THE NATURAL COURSE OF MYASTHENIA GRAVIS AND EFFECT OF THERAPEUTIC MEASURESAnnals of the New York Academy of Sciences, 1981